Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

More on GLP-1 and incretin signalling

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• GLP-1 receptor agonists link to lower stroke and Alzheimer risk

  Neurology Genetics · 4 Oct 2026

• Genetically proxied GIP pathway links to lower fracture risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026